DEA's Diversion Control Division posted this joint letter from DEA and HHS supporting the expansion of Medications for Opioid Use Disorder (MOUD). DEA and HHS support the expansion of MOUD especially in rural or underserved areas.

DEA is asking its registrants to ensure an adequate and uninterrupted supply of MOUD products when appropriately prescribed and asks distributors to examine any quantitative thresholds they established to ensure that individuals with OUD are able to access buprenorphine.

Expanding access to MOUD is one more way to assist patients with OUD during the Opioid Public Health Emergency.

Read More